China Medical GatewayLoading your healthcare gateway…

Other Solid Tumors in China

Overview

This program covers the full range of solid tumors beyond the major site-specific programs — including kidney, bladder, esophageal, thyroid, head-and-neck and other cancers — each treated by dedicated multidisciplinary teams.

China’s national cancer network offers site-specific surgical teams, precision radiotherapy and access to domestically developed targeted and immune oncology drugs alongside international agents.

Symptoms & Signs

Symptoms depend on the organ involved: blood in urine (bladder, kidney), difficulty swallowing (esophagus), neck lumps (thyroid)

Unexplained weight loss, night sweats or persistent fatigue common across advanced cancers

New, persistent pain in any body region that does not resolve

A noticeable or palpable mass anywhere on the body

Changes in bowel or bladder function lasting weeks

Chronic cough or hoarseness beyond three weeks

Diagnosis

Organ-focused imaging: ultrasound, contrast CT or MRI as first-line

Endoscopy for luminal cancers (esophagus, stomach, colon, bladder)

Image-guided core needle biopsy establishing tissue diagnosis

Molecular profiling (NGS) identifying actionable mutations

PET-CT for whole-body staging and response assessment

Tumor markers where clinically informative for monitoring

Treatment Options

Site-specific oncologic surgery by dedicated surgical teams

Minimally invasive laparoscopic and robotic approaches where appropriate

Precision radiotherapy: IMRT, VMAT and SBRT for local control

Systemic chemotherapy tailored to tumor type and patient fitness

Targeted therapy and immunotherapy for actionable molecular profiles

Multidisciplinary tumor-board review individualizing every treatment plan

Advanced Technologies & Novel Drug

da Vinci surgical platforms across urologic, thoracic and abdominal cancers

Next-generation sequencing informing targeted drug selection

Advanced radiotherapy with online adaptive planning

Interventional oncology: TACE, ablation and portal-vein embolization

Novel antibody-drug conjugates and immunotherapy combinations available at major centers

Hospital & Specialist

Return to Home